WuXi Biologics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

WuXi Biologics is a Chinese headquartered organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics’ roots date back to 2010 when it was established as a business unit of WuXi AppTec, began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. Since then, WuXi Biologics has focused on establishing state-of-the-art research and manufacturing facilities and building partnerships with pharmaceutical and biotech companies in the space.[1] WuXi Biologics ultimately spun out of WuXi AppTec in 2015 and two years later went public on the Hong Kong Stock Exchange in June of 2017[2].

Dundalk, Ireland Facility[edit]

In April of 2018,[3] WuXi Biologics announced plans to build a new biologics drug substance manufacturing facility on 26 hectares in Dundalk, Ireland. The project is directly supported by the Irish Government through IDA Ireland, with a cost of approximately $394 million. When completed, the facility will be one of the world's largest plants supporting single-use bioreactors and will help accelerate the development of biologic drugs in Europe. [4]

References[edit]

  1. ^ "CHNA ETF Video Series: WuXi Biologics". loncarfunds.com. Retrieved 2019-08-14.
  2. ^ "UPDATE 2-WuXi Biologics prices HK IPO at top as investors seek..." Reuters. 2017-06-06. Retrieved 2019-08-14.
  3. ^ "WuXi Biologics' Biologics Manufacturing Facility, Dundalk, Ireland". Pharmaceutical Technology. Retrieved 2019-08-14.
  4. ^ "Jacobs Wins Contract to Provide Construction Services for WuXi". GEN - Genetic Engineering and Biotechnology News. 2019-06-10. Retrieved 2019-08-14.